What is the current stock price of FibroGen, Inc. (FGEN)?

As of the latest market data, FibroGen, Inc. (FGEN) is trading at $9.07. The stock has seen a loss of -1.63% today.

Does FibroGen, Inc. (FGEN) pay a dividend?

Based on current data, FibroGen, Inc. does not have a confirmed active dividend policy.

What is the market cap of FibroGen, Inc.?

The current market capitalization of FibroGen, Inc. (FGEN) is approximately unavailable.

FGEN

FibroGen, Inc.·Healthcare

9.07

1.627%(−0.15)

Market Closed

10.00

10.254%(+0.93)

After Hours

Last Updated: — ET

52W L: $4.8552W H: $21.95

FGEN NEWS

globenewswire.com

Mar 9

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

globenewswire.com

Feb 23

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) from the investigator-sponsored Phase 1b/2 study will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026 in San Francisco, CA.

defenseworld.net

Jan 24

FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why

FibroGen, Inc (NASDAQ: FGEN - Get Free Report) shares crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $8.96 and traded as high as $9.75. FibroGen shares last traded at $9.77, with a volume of 31,125 shares trading hands. Analyst Ratings Changes Separately, Weiss

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

225

IPO Date

2014-11-14

Beta

0.77

Websitewww.fibrogen.com↗